World's Best Scientists 2026 revealed!
Philip F. Halloran

Philip F. Halloran

D-Index & Metrics

Medicine

D-Index
115
Citations
56724
World Ranking
4493
National Ranking
174

Philip F. Halloran publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Philip F. Halloran sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 552 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Philip F. Halloran D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Philip F. Halloran sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 115 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2007 - Fellow of the Royal Society of Canada Academy of Science

Overview

Philip F. Halloran is affiliated with the University of Alberta in Canada and specializes primarily in the field of Medicine, with a focused emphasis on Transplantation and related subfields. Their research intersects significant clinical and biological aspects of organ transplantation, especially kidney transplantation.

Their work encompasses several subfields including:

  • Transplantation
  • Surgery
  • Epidemiology
  • Nephrology
  • Immunology

Philip F. Halloran has contributed extensively to topics such as:

  • Renal Transplantation Outcomes and Treatments
  • Transplantation: Methods and Outcomes
  • Organ Transplantation Techniques and Outcomes
  • Renal Diseases and Glomerulopathies
  • Viral Infections and Immunology Research
  • Organ Donation and Transplantation
  • Cytomegalovirus and herpesvirus research

Their publication record includes contributions to prominent journals such as Transplantation, American Journal of Transplantation, The Journal of Heart and Lung Transplantation, Journal of the American Society of Nephrology, and Transplant International.

Selected recent papers authored or co-authored by Philip F. Halloran include:

  • "Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes," 2022, American Journal of Transplantation
  • "The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics," 2023, American Journal of Transplantation
  • "A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection," 2020, Journal of the American Society of Nephrology
  • "CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection," 2020, Transplantation
  • "Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies," 2020, Journal of the American Society of Nephrology

Frequent collaborators include:

  • Katelynn S. Madill-Thomsen
  • Georg A. Böhmig
  • Martina Macková
  • Farsad Eskandary
  • Klemens Budde

Philip F. Halloran has been recognized as a Fellow of the Royal Society of Canada since 2007, under the Academy of Science category.

Best Publications

  • The Banff 97 working classification of renal allograft pathology

    Lorraine C. Racusen;Kim Solez;Robert B. Colvin;Stephen M. Bonsib

  • Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

    K. Solez;R. B. Colvin;L. C. Racusen;M. Haas

  • Reduced exposure to calcineurin inhibitors in renal transplantation.

    Henrik Ekberg;Helio Tedesco-Silva;Alper Demirbas;Štefan Vítko

  • Immunosuppressive Drugs for Kidney Transplantation

    Philip F. Halloran

  • International standardization of criteria for the histologic diagnosis of renal allograft rejection : the Banff working classification of kidney transplant pathology

    K.i.m. Solez;Roy A. Axelsen;Hallgrimur Benediktsson;James F. Burdick

  • Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.

    J. Sellarés;D. G. de Freitas;M. Mengel;J. Reeve

  • Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').

    K. Solez;R. B. Colvin;L. C. Racusen;B. Sis

  • Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

    Lorraine C. Racusen;Robert B. Colvin;Kim Solez;Michael J. Mihatsch

  • Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation

    F. Vincenti;R. Kirkman;S. Light;G. Bumgardner

  • The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials

    M. Haas;A. Loupy;C. Lefaucheur;C. Roufosse

  • Costimulation blockade with belatacept in renal transplantation.

    Flavio Vincenti;Christian Larsen;Antoine Durrbach;Thomas Wekerle

  • A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation

    Paul Keown;Pekka Häyry;Peter Morris;Calvin Stiller

  • Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups

    B. Sis;M. Mengel;M. Haas;R. B. Colvin

  • Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

    P Halloran;T Mathew;S Tomlanovich;C Groth

  • Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.

    G. Einecke;B. Sis;J. Reeve;M. Mengel

  • Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.

    Robert S. Gaston;J. Michael Cecka;Bert L. Kasiske;Ann M Fieberg

  • Rethinking chronic allograft nephropathy: the concept of accelerated senescence.

    Philip F. Halloran;Anette Melk;Claudia Barth

  • Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining.

    Banu Sis;Gian S. Jhangri;Sakarn Bunnag;Kara Allanach

  • Banff 2011 Meeting Report: New Concepts in Antibody‐Mediated Rejection

    M. Mengel;B. Sis;M. Haas;R. B. Colvin

  • The temporal profile of calcineurin inhibition by cyclosporine in vivo.

    Philip F. Halloran;Lisa M. H. Helms;Lina Kung;Jean Noujaim

Frequent Co-Authors

Michael Mengel
Michael Mengel University of Alberta
Bruce Kaplan
Bruce Kaplan University of Colorado Anschutz Medical Campus
Arthur J. Matas
Arthur J. Matas University of Minnesota
Lorraine C. Racusen
Lorraine C. Racusen Johns Hopkins University School of Medicine
Robert B. Colvin
Robert B. Colvin Harvard University
Mark D. Stegall
Mark D. Stegall Mayo Clinic
Joaquín Madrenas
Joaquín Madrenas University of California, Los Angeles
Jonathan S. Bromberg
Jonathan S. Bromberg University of Maryland, Baltimore
Richard N. Fedorak
Richard N. Fedorak University of Alberta

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine goes beyond traditional MD programs. Many students and professionals in the healthcare field are choosing flexible online degrees to advance their careers while managing other responsibilities.

For those interested in healthcare administration, it’s essential to look for which online healthcare degree programs are recognized for their accreditation by cahme? Accredited programs ensure quality education and can open doors to leadership roles.

Registered nurses seeking career advancement but aiming to avoid additional clinical requirements may consider rn to bsn with no clinicals programs. These options provide a faster pathway to a BSN and greater professional flexibility.

Advanced nursing degrees can further boost career opportunities. If you’re looking for efficiency, check out the shortest dnp programs. For those concerned about costs, there are also affordable dnp programs that make higher education more accessible.

These varied pathways highlight the range of options available for students and healthcare professionals seeking to expand their expertise and career potential in the U.S. medical field.

Best Scientists Citing Philip F. Halloran

Trending Scientists

Recently Published Articles